A Leading Biomedicine Innovator
For Cancers & Degenerative Diseases
Statements in this presentation relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include those regarding our ability to implement our plans, strategies and objectives for future operations, including our plan to configure part of our Shanghai facility with GE Healthcare’s FlexFactory platform, our ability to execute on proposed new products, services or development thereof, results of our clinical research and development, regulatory infrastructure governing cell therapy and cellular biopharmaceuticals, our ability to enter into agreements with any necessary manufacturing, marketing and/or distribution partners for purposes of commercialization, our ability to seek intellectual property rights for our product candidates, competition in the industry in which we operate, overall market conditions, any statements or assumptions underlying any of the foregoing and other risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

This presentation is strictly intended to provide general information about our company and business. Neither this presentation nor any part hereof constitutes an offer of securities.
NASDAQ listed biopharmaceutical company focused on the development and commercialization of innovative cell therapies for the China market

Fully integrated cell therapy platform with best-in-class manufacturing in China, including major partnerships with **GE Healthcare Life Sciences China & Thermo Fisher Scientific**

Uniquely positioned to be the leading cell therapy company in the China market as the partner of choice for Western companies looking to enter China and through attractive proprietary programs in **immuno-oncology and stem cell therapy**

Seasoned management team with decades of global technology and large pharma leadership experience; exceptional scientific advisory board; strong institutional investment base
Recent Milestones Achieved

**CAR-T Therapies**
- **CARD-1** (C-CAR011, CD19) clinical trial in DLBCL & NHL
- **CALL-1** (C-CAR011, CD19) clinical trial in Adult ALL
  - IND applications accepted by CFDA for “C-CAR011” anti-CD19 CAR-T therapy, for the treatment of B-cell NHL and ALL

**Adipose-Derived Progenitor Cell for Knee Osteoarthritis (KOA)**
- Robust preclinical data package
- Successfully completed Phase IIb ReJoin® autologous trial
- Successfully completed Phase I AlloJoin™ allogeneic trial

**International standard GMP Facilities**
- Strategic collaboration with GE Healthcare Life Sciences China to establish joint technology laboratory
- Strategic Partnership with Thermo Fisher Scientific China Ltd. to build joint Cell Therapy Technology Innovation and Application Center
- 70,000 sq. ft. in three major Chinese cities
  - Capable of treating up to 10,000 cancer patients per year (CAR-T)
  - Capable of treating up to 10,000 KOA patients per year (Stem Cell)
C-CAR011 CARD-1 & CALL-1
Phase I Clinical Trial Designs

CARD-1: Phase I Trial in Chemo-Refractory DLBCL

Key Eligibility Criteria:
- Refractory DLBCL
- According to Scholar-1 criteria
- ECOG 0-1

Primary Outcome Measures:
- Safety (DLT and TEAEs in 28 days)

Secondary Outcome Measures:
- ORR (CR+PR) in 12 weeks
- DCR in 12 weeks

Operational:
- Single Center
- Using 3+3 dose escalation design, enroll up to 18 patients

CALL-1: Phase I Trial in Relapsed/Refractory Adult ALL

Key Eligibility Criteria:
- Refractory and Relapsed Adult ALL
- ECOG 0-1

Primary Outcome Measures:
- Safety (DLT and TEAEs in 28 days)

Secondary Outcome Measures:
- ORR (CR+CRi) and MRD- in 8 weeks
- OS in 6 month

Operational:
- Single Center
- Using 3+3 dose escalation design, enroll up to 18 patients
## C-CAR011 Ongoing Clinical Trials

<table>
<thead>
<tr>
<th>TRIAL</th>
<th>2016</th>
<th></th>
<th></th>
<th></th>
<th>2017</th>
<th></th>
<th></th>
<th></th>
<th>2018</th>
<th></th>
<th></th>
<th></th>
<th>2019</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q4</td>
<td>Q1</td>
<td>Q2</td>
<td>Q3</td>
<td>Q4</td>
<td>Q1</td>
<td>Q2</td>
<td>Q3</td>
<td>Q4</td>
<td>Q1</td>
<td>Q2</td>
<td>Q3</td>
<td>Q4</td>
<td>Q1</td>
<td>Q2</td>
<td>Q3</td>
</tr>
<tr>
<td>CARD-1 (DLBCL)</td>
<td>PHASE I</td>
<td>PHASE II</td>
<td></td>
<td></td>
<td>Last Patient In</td>
<td>Topline Data</td>
<td></td>
<td></td>
<td></td>
<td>Last Patient In</td>
<td>Topline Data</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CALL-1 (Adult ALL)</td>
<td>PHASE I</td>
<td>PHASE II</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# Immuno-Oncology Pipeline

<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
<th>Pre-Clinical</th>
<th>Phase I</th>
<th>Phase II</th>
</tr>
</thead>
<tbody>
<tr>
<td>C-CAR011 (anti-CD19)</td>
<td>DLBCL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>B-cell ALL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-CD20 CAR</td>
<td>NHL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-CD22 CAR</td>
<td>B-cell ALL, HCL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD20-CD19 Bispecific CAR</td>
<td>NHL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-BCMA CAR</td>
<td>MM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AFP TCR-T</td>
<td>HCC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NKG2D CAR</td>
<td>AML</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TIL(combo w/ anti- PD-1)</td>
<td>NSCLC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other solid tumors</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Legend:**
- B-cell ALL = B-cell acute lymphoblastic leukemia
- DLBCL = diffuse large B cell lymphoma
- MM = multiple myeloma
- AML = acute myeloid leukemia
- NHL = non-Hodgkin lymphoma
- NSCLC = Non small cell lung cancer
- HCC = hepatocellular carcinoma

**Dates:**
- 15/08/2018
<table>
<thead>
<tr>
<th>TECHNOLOGY</th>
<th>INDICATION</th>
<th>PRE-CLINICAL</th>
<th>PHASE I</th>
<th>PHASE II</th>
<th>PHASE III</th>
</tr>
</thead>
<tbody>
<tr>
<td>haMPC</td>
<td>ReJoin® (Autologous)</td>
<td>KOA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AlloJoin™ (Allogeneic)</td>
<td>KOA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- ReJoin® Phase IIb met primary and secondary end-points
  - Safe, and provide both symptom relief and cartilage regeneration
- AlloJoin™ Phase I 48-week data demonstrated safety and tolerability
- Regulatory path for stem cells in China has been rolled out recently, requiring IND/NDA application like other drugs

haMPC = Human Adipose Derived Mesenchymal Progenitor Cells
KOA = Knee Osteoarthritis

15/08/2018
State-of-the-Art R&D and GMP Facilities

Current Total GMP Facility: 70,000 sq ft

- Plasmid Manufacture
- Virus Manufacture (BSL-2)
- CART Manufacture I (BSL-2, B)
- CART Manufacture II (BSL-2, C)
- hMSC Manufacture
- QC Testing Centre
- Key reagent preparation

✓ Conforming to regulatory requirements
✓ Strong and independent QA system
✓ 1000+ SMP/SOP
✓ Skilled staff

15/08/2018
Integrated CMC for CAR-T Cell Therapy

Plasmid Production
- GMP grade
- High capacity: 1-10 g/lot
- Low endotoxin: <0.01 EU/mg
- High transfection rate

Viral Vectors Production
- GMP grade
- Strong capacity: Lentin, Retro, AAV, Ad
- Automated purification process
- High titer: >10^7 Tu/ml

CAR-T Cells Production
- Standardization/centralized
- Automation/closed system
- Serum free
- High positive rate, 50%-90%
- High yield: 3~5e9
- High viability: >90%
- Clinic grade frozen products

CAR-T GMP FACILITY
Centralized and Automated Process

Hospital 1
Hospital 2
Hospital 3
Hospital 4
Hospital 5

CBMG Shanghai

Sample procurement & processing
Selection & Expansion
Cryo-preserved products

CBMG Wuxi
Library of Plasmid, Virus, Reagents, Stem Cells

109 QC assays for CAR-T
59 QC assays for stem cells

Tech Transfer
Intermediates
Aiming to support simultaneous clinical trials for various products and multi-centers

**FACILITY EXPANSION**

- Wuxi GMP facility has just been expanded to 27,000 sq ft
- Shanghai GMP facility has approximately 40,000 sq. ft.

**PROCESS IMPROVEMENT**

- 90% closed system
- Predominantly automated system

Built-up capacity to support product commercialization in the near future

- Total GMP Facility space across China: **70,000 sqft**
- Total **22** independent production lines; **53** clean rooms
  - Treat **10,000** Cancer Patients/year
  - Treat **10,000** KOA Patients/year
Recent GMP Advancements: Strategic Partnerships with GE Healthcare Life Sciences China

Strategic Partnership signed to Establish Joint Technology Laboratory

- Joint lab within CBMG’s new Shanghai Zhangjiang GMP-facility
- Co-develop high-quality industrial control processes in CAR-T & stem cell manufacturing
- Joint R&D of fully integrated and automated immunotherapy cell preparation system

Plan signed to Accelerate CBMG Cell Therapy Manufacturing with GE’s New Start-to-Finish Solution

- First GE Healthcare FlexFactory™ for cell therapy installation in the world
- Expected to provide CBMG with scalable, fully-equipped cell therapy manufacturing capabilities, training and services
CBMG and Thermo Fisher Scientific (China) Ltd. Strategic Partnership to build joint Cell Therapy Technology Innovation and Application Center

- Joint laboratory with CBMG’s new Shanghai Zhangjiang GMP-facility
- Focuses on research & development of an automated cell therapy manufacturing system
Recent GMP Advancements: Shanghai GMP Expansion

November 2017: Grand Opening of new Shanghai Flagship GMP Facility

- 100,000-square-foot space with a top-of-the-line GMP facility
- Launched “CBMG-GE Joint Laboratory of Cell Therapy”
- Launched “CBMG-Thermo Fisher Scientific Joint Innovation & Application Center”
### China Market

- **U.S. drug pricing pressure not applicable in the China market**

- **China CFDA Cell Therapy Regulation**
  - Clarification of regulation in late December, 2017
  - Substantial barrier-to-entry for newcomers
  - A clear path for CBMG to advance pipeline from clinical development to commercialization
  - A seasoned team, first mover advantage, and manufacturing capabilities make CBMG highly distinguishable

- **China Landscape**
  - Aging: China has a rapidly aging population: over 20% of the 1.4 billion people are over 55 years old
  - Urbanization & Stressful Lifestyle: China has added more than 500 million people to its cities in the past 35 years
  - Approximately 5M new cancer patients annually
  - 57M Knee Osteoarthritis patients [International Journal of Rheumatic Diseases, 2011]
<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bizuo (Tony) Liu</td>
<td>Chief Executive Officer, Executive Director</td>
<td>Alibaba Group</td>
</tr>
<tr>
<td>Helen Zhang</td>
<td>Chief Production Officer</td>
<td>Microsoft</td>
</tr>
<tr>
<td>Chase Dai, PhD, MD</td>
<td>General Manager</td>
<td>AstraZeneca MedImmune</td>
</tr>
<tr>
<td>JiaQiang Ren, PhD</td>
<td>Sr. Director</td>
<td>AbbVie</td>
</tr>
<tr>
<td>Grace He, MD</td>
<td>Corporate Vice President</td>
<td>Regeneron</td>
</tr>
<tr>
<td>Andrew Chan, JD, MBA</td>
<td>Chief Legal Officer, Corporate Development &amp; Secretary</td>
<td>Medgene</td>
</tr>
</tbody>
</table>
Scientific & External Advisors

Michael Caligiuri, PhD MD
Chair of External Advisory Board
AACR, The James Cancer Center
ORIEN

Alan List, MD
Chair of Scientific Advisory Board
President and CEO of Moffitt Cancer Center and Research Institute

Robert S. Langer, PhD, ScD
Scientific Advisor
Professor, Koch Institute for Integrative Cancer Research at MIT; Former member United States Food and Drug Administration’s SCIENCE Board

Guo-Tong Xu, MD, PhD
Scientific Advisor
Professor of Ophthalmology and Regenerative Medicine, Dean of Tongji University School of Medicine; Director of Stem Cell Bank of TUSM

Scott J. Antonia, MD, PhD
Scientific Advisor
Program Leader, Immunology Program at Moffitt Cancer Center; Professor of Oncology at USF College of Medicine
Saving Life

Revitalizing Life

WWW.CELLBIOMEDGROUP.COM